Glycopeptide Antibiotics Market, by Drug (Vancocin, Orbactiv, Dalvance, Kimyrsa, and Others), by Disease Indication (Clostridium difficile-associated Diarrhea, Endocarditis, Skin Structure Infections, and Others), by Distribution channel (Hospital Pharmac

Glycopeptide Antibiotics Market, by Drug (Vancocin, Orbactiv, Dalvance, Kimyrsa, and Others), by Disease Indication (Clostridium difficile-associated Diarrhea, Endocarditis, Skin Structure Infections, and Others), by Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Glycopeptide antibiotics are the type of antibiotics that inhibit bacterial cell wall formation by inhibiting peptidoglycan synthesis. Glycopeptide antibiotics are used for the treatment of Clostridium difficile-associated diarrhea, endocarditis, enterocolitis Pneumonia acquired during a hospital stay or that develops while using a ventilator, and severe skin and skin structure infections. Gram-positive bacteria, which do not have an outer membrane covering their cell walls, and gram-negative bacteria, which have an additional membrane covering the cell walls, are the two main types of bacteria that cause infections. Gram-negative bacteria are resistant to glycopeptides because they have an outer membrane that prevents the entry of glycopeptides into their cell wall, although glycopeptides are effective against gram-positive bacterial infections.

Moreover, some glycoproteins are administered through the intravenous route in severe infection and oral treatment is used at the time of mild infection. Life-threatening infections brought on by multidrug-resistant Gram-positive organisms like Staphylococcus aureus, Enterococcus species, and Clostridium difficile are routinely treated using glycopeptide antibiotics (GPAs). One of a group of antibiotics has structures that contain either a glycosylated cyclic or polycyclic nonribosomal peptide that was first isolated from plant and soil bacteria. By preventing the manufacture of peptidoglycan, these antibiotics interfere with the cell wall construction of organisms that are sensitive (mostly Gram-positive cocci). Vancomycin, teicoplanin, and ramoplanin are examples of first-generation glycopeptide antibiotics. Oritavancin, dalbavancin, and telavancin are examples of second-generation semi-synthetic glycopeptide antibiotics.

Market Dynamics

Increasing product launch and approval of glycopeptide antibiotics are expected to drive the market growth over the forecast period. For instance, in June 2019, ANI Pharmaceuticals, Inc., a biopharmaceutical company received the U.S. FDA prior approval supplement for its Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml for the treatment of various infections.

Key features of the study:

• This report provides an in-depth analysis of the global glycopeptide antibiotics market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global glycopeptide antibiotics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global glycopeptide antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global glycopeptide antibiotics market

Detailed Segmentation:

• Global Glycopeptide Antibiotics Market, By Drug:
• Vancocin
• Orbactiv
• Dalvance
• Kimyrsa
• Others
• Global Glycopeptide Antibiotics Market, By Disease Indication:
• Clostridium difficile-associated Diarrhea
• Endocarditis
• Skin Structure Infections
• Others
• Global Glycopeptide Antibiotics Market, By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Global Glycopeptide Antibiotics Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• U.K.
• Germany
• France
• Spain
• Italy
• Russia
• Rest Of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region
• South Africa
• Central Africa
• North Africa
• Company Profiles
• ANI Pharmaceuticals, Inc.*
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
• Fresenius SE & Co. KGaA
• Pfizer Inc
• Mylan N.V.
• Novartis AG
• Hikma Pharmaceuticals plc
• Aurobindo Pharma
• AbbVie Inc.
• Melinta Therapeutics, Inc
• Cumberland Pharmaceuticals Inc
• Theravance Biopharma
• Janssen Global Services, LLC
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.

“*” marked represents similar segmentation in other categories in the respective section.